Twist Bioscience (NASDAQ:TWST) Stock Price Expected to Rise, Scotiabank Analyst Says

Twist Bioscience (NASDAQ:TWST) had its price target raised by investment analysts at Scotiabank from $54.00 to $62.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “sector outperform” rating on the stock. Scotiabank’s price objective would indicate a potential upside of 20.27% from the company’s previous close.

Several other equities analysts have also commented on TWST. Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday. Barclays reduced their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 19th. Wolfe Research started coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Leerink Partners raised their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Finally, TD Cowen restated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $53.80.

Twist Bioscience Price Performance

NASDAQ TWST traded down $1.20 during trading on Tuesday, reaching $51.55. The company’s stock had a trading volume of 163,463 shares, compared to its average volume of 738,680. The stock has a market capitalization of $3.06 billion, a PE ratio of -14.44 and a beta of 1.87. The firm has a fifty day moving average of $48.52 and a 200 day moving average of $46.23. Twist Bioscience has a one year low of $27.41 and a one year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The company’s revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.75) EPS. Research analysts expect that Twist Bioscience will post -2.27 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In other news, SVP Paula Green sold 5,519 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $246,147.40. Following the sale, the senior vice president now directly owns 115,494 shares in the company, valued at approximately $5,151,032.40. This represents a 4.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 14,334 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $639,296.40. Following the completion of the sale, the chief executive officer now owns 589,552 shares in the company, valued at approximately $26,294,019.20. The trade was a 2.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 80,407 shares of company stock valued at $3,757,443 over the last 90 days. Company insiders own 3.01% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Wilmington Savings Fund Society FSB purchased a new position in Twist Bioscience during the 3rd quarter worth $34,000. Van ECK Associates Corp increased its holdings in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after purchasing an additional 267 shares during the period. Signaturefd LLC increased its holdings in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the period. Beaird Harris Wealth Management LLC purchased a new position in Twist Bioscience during the 3rd quarter worth $95,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.